{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T02:41:43Z","timestamp":1782873703937,"version":"3.54.5"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,10,6]],"date-time":"2009-10-06T00:00:00Z","timestamp":1254787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,10,6]],"date-time":"2009-10-06T00:00:00Z","timestamp":1254787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatology"],"abstract":"<jats:p>We undertook a prospective, multicentre, double-blind, placebo controlled, randomised, parallel-group study to evaluate the efficacy and safety of the topical 1% emulsion gel formulation of Lamisil\u00ae in the treatment of tinea corporis\/cruris. Eighty-three patients with clinically and mycologically confirmed tinea corporis\/cruris were enrolled from 6 dermatology practices. Of the 62 patients in the intent-to-treat population, 29 were randomised to 1% Lamisil emulsion gel (23 male, 6 female; mean age 42 years, range 19\u201379 years) and 33 to placebo (25 male, 8 female; mean age 36 years, range 16\u201373 years). The gels were applied once daily for 1 week. Mycological cure (negative microscopy and culture results) and effectiveness of treatment (mycological cure plus no or minimal signs and symptoms) were measured on day 7, weeks 2, 4 and 8, and at the end of the study. At the study end, rates of mycological cure were 83% for Lamisil 1% emulsion gel and 27% for placebo gel (p &lt; 0.001), with respective rates for effective treatment of 83 and 21% (p &lt; 0.001). Complete cure was recorded for 59% of patients receiving Lamisil 1% emulsion gel and 13% of patients receiving placebo gel (p &lt; 0.001). We conclude that a 1-week course of Lamisil 1% emulsion gel is significantly more effective in the treatment of tinea corporis\/cruris than placebo gel in respect of complete cure, mycological cure and effective treatment.<\/jats:p>","DOI":"10.1159\/000246177","type":"journal-article","created":{"date-parts":[[2009,10,7]],"date-time":"2009-10-07T07:08:20Z","timestamp":1254899300000},"page":"14-18","source":"Crossref","is-referenced-by-count":14,"title":["Tinea corporis\/cruris: New Treatment Options"],"prefix":"10.1159","author":[{"given":"J.S.","family":"van Heerden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.F.","family":"Vismer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2009,10,6]]},"container-title":["Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/246177","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000246177","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:14:13Z","timestamp":1777540453000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000246177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,6]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000246177","archive":["Portico"],"relation":{},"ISSN":["1018-8665","1421-9832"],"issn-type":[{"value":"1018-8665","type":"print"},{"value":"1421-9832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,6]]}}}